{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:40:39Z","timestamp":1791877239143,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.xphs.2018.09.036","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T13:27:41Z","timestamp":1539264461000},"page":"268-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Irrelevance of In\u00a0Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping"],"prefix":"10.1016","volume":"108","author":[{"given":"Michael B.","family":"Bolger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce S.","family":"Macwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sarfraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Almukainzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2018.09.036_bib1","first-page":"205","article-title":"Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration","volume":"57","author":"Teorell","year":"1937","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.xphs.2018.09.036_bib2","first-page":"226","article-title":"Kinetics of distribution of substances administered to the body, II: the intravascular modes of administration","volume":"57","author":"Teorell","year":"1937","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.xphs.2018.09.036_bib3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9343(59)90346-8","article-title":"Anatomy of body water and electrolytes","volume":"27","author":"Edelman","year":"1959","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.xphs.2018.09.036_bib4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jps.2600570814","article-title":"Thiopental pharmacokinetics","volume":"57","author":"Bischoff","year":"1968","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.036_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF02353860","article-title":"Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125","volume":"22","author":"Kawai","year":"1994","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/15287399509532021","article-title":"An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data","volume":"46","author":"Poulin","year":"1995","journal-title":"J\u00a0Toxicol Environ Health"},{"key":"10.1016\/j.xphs.2018.09.036_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental transit and dispersion model analysis of small intestinal transit flow in humans","volume":"140","author":"Yu","year":"1996","journal-title":"Int J Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2018.09.036_bib8","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2018.09.036_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejps.2015.06.020","article-title":"Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human","volume":"77","author":"Wang","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.036_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1208\/s12248-015-9781-1","article-title":"Application of absorption modeling in rational design of drug product under quality-by-design paradigm","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.036_bib11","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1111\/febs.13253","article-title":"Lysosomal proteins in cell death and autophagy","volume":"282","author":"Mrschtik","year":"2015","journal-title":"FEBS J"},{"issue":"8","key":"10.1016\/j.xphs.2018.09.036_bib12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4155\/bio.09.128","article-title":"Mechanisms of amine accumulation in, and egress from, lysosomes","volume":"1","author":"Goldman","year":"2009","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.036_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A\u00a0high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol In\u00a0Vitro"},{"issue":"18","key":"10.1016\/j.xphs.2018.09.036_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","article-title":"Commentary. Lysosomotropic agents","volume":"23","author":"de Duve","year":"1974","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0278-5846(02)00317-2","article-title":"Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions","volume":"27","author":"Daniel","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.xphs.2018.09.036_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.036_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2133\/dmpk.20.177","article-title":"Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers","volume":"20","author":"Takashima","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.036_bib18","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1172\/JCI116441","article-title":"Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans","volume":"91","author":"Evans","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"8563","key":"10.1016\/j.xphs.2018.09.036_bib19","first-page":"852","article-title":"Low frequency of slow debrisoquine hydroxylation in a native Chinese population","volume":"2","author":"Lou","year":"1987","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xphs.2018.09.036_bib20","first-page":"1514","article-title":"Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in\u00a0vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?","volume":"29","author":"Yu","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.036_bib21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jpba.2004.02.033","article-title":"Development of a chromatographic bioreactor based on immobilized beta-glucuronidase on monolithic support for the determination of dextromethorphan and dextrorphan in human urine","volume":"35","author":"Calleri","year":"2004","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clpt.2003.09.013","article-title":"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in\u00a0vivo","volume":"75","author":"Gorski","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2018.09.036_bib23","first-page":"493","article-title":"Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers","volume":"25","author":"Silvasti","year":"1987","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.036_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2125.1994.tb04348.x","article-title":"The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in\u00a0vitro studies using human liver microsomes","volume":"38","author":"Kerry","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.036_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1208\/s12248-009-9107-2","article-title":"Prediction of modified release pharmacokinetics and pharmacodynamics from in\u00a0vitro, immediate release, and intravenous data","volume":"11","author":"Lukacova","year":"2009","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib26","first-page":"26","article-title":"The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in\u00a0vitro studies with rat everted gut sacs","volume":"10","author":"Arellano","year":"2007","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.036_bib27","first-page":"258","article-title":"Estimation of aqueous solubility by the general solubility equation (GSE) the easy way","volume":"22","author":"Sanghvi","year":"2003","journal-title":"Mol Inform"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.036_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/138920008783571765","article-title":"Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein","volume":"9","author":"Kanaan","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.111.042200","article-title":"Prediction of relative in\u00a0vivo metabolite exposure from in\u00a0vitro data using two model drugs: dextromethorphan and omeprazole","volume":"40","author":"Lutz","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2018.09.036_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejps.2016.07.001","article-title":"Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6","volume":"92","author":"Chen","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.036_bib31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/jm901371v","article-title":"Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination","volume":"53","author":"Varma","year":"2010","journal-title":"J\u00a0Med Chem"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.036_bib32","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1002\/jps.22550","article-title":"PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach","volume":"100","author":"Poulin","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.036_bib33","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/jps.20419","article-title":"An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery","volume":"94","author":"Parrott","year":"2005","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.036_bib34","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1124\/dmd.107.015644","article-title":"Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs","volume":"35","author":"De Buck","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.xphs.2018.09.036_bib35","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/00498250902954296","article-title":"Prediction of phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling","volume":"39","author":"Gibson","year":"2009","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.036_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11539680-000000000-00000","article-title":"Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling","volume":"50","author":"Jones","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2018.09.036_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"IMI\u2013oral biopharmaceutics tools project\u2013evaluation of bottom-up PBPK prediction success part 2: an introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2006.10.001","article-title":"Current perspectives in dissolution testing of conventional and novel dosage forms","volume":"328","author":"Azarmi","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2018.09.036_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/jps.2600520629","article-title":"Per cent absorbed time plots derived from blood level and\/or urinary excretion data","volume":"52","author":"Wagner","year":"1963","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2018.09.036_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jps.2600570602","article-title":"New method for calculating the intrinsic absorption rate of drugs","volume":"57","author":"Loo","year":"1968","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2008.10.019","article-title":"Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products","volume":"72","author":"Okumu","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.036_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2006.05.004","article-title":"Biorelevant dissolution media as a predictive tool for glyburide a class II drug","volume":"29","author":"Wei","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2018.09.036_bib43","series-title":"U.S. Food and Drug Administration. Dissolution testing and specification criteria for immediate-release solid oral dosage forms containing biopharmaceutics classification system class 1 and 3 drugs","year":"2015"},{"key":"10.1016\/j.xphs.2018.09.036_bib44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/DDDT.S131213","article-title":"Justification of disintegration testing beyond current FDA criteria using in\u00a0vitro and in silico models","volume":"11","author":"Uebbing","year":"2017","journal-title":"Drug Des Devel Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:23:48Z","timestamp":1758360228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918305999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0022354918305999"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.09.036","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Irrelevance of In\u00a0Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}